Elicio Therapeutics Inc. (ELTX) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Elicio Therapeutics Inc. (NASDAQ: ELTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $1.59 (-5.36% 1D, market cap $45.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ELTX ranks #866 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELTX carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MREO (Mereo BioPharma Group plc) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $46.2M) and BMEA (Biomea Fusion Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $46.4M). Among the 5-stock peer group, ELTX leads on earnings multiple (N/A) while DWTX leads on capital efficiency (-32.3% ROIC).
Per ELTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001601485), Elicio Therapeutics Inc. generated $105.6M in revenue (-16.2% YoY), -$39.6M in net income, and -$37.0M in free cash flow against $25.9M in total assets and $9.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
While ELTX currently carries a cautious 28/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.01) and Max Pain ($1.67) forces dealer call-delta covering toward $16.80.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Elicio Therapeutics Inc. (ELTX) dropped -5.36% to $1.59, trading at 2% of its 52-week range ($1.44 – $16). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo! Finance Canada report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.
marketscreener.com report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.
The Manila Times report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.
Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the
Multiple pre-specified subgroup analyses favored camupepimut (ELI-002 7P), including patients with and without detectable baseline ctDNA.Encouraging disease-free survival outcomes were observed in both ctDNA-negative (HR
Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced results
Gainers Lucid Diagnostics (NASDAQ:LUCD) stock moved upwards by 41.9% to $0.46 during Thursday's after-market session. The company's market cap stands at $67.1 million. Aardvark Therapeutics (NASDAQ:AARD) stock
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -16.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ELTX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ELTX. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Elicio Therapeutics Inc. (ELTX) ranks #866 by composite RQD confidence (28/100, grade E) and #759 by equity capitalization ($45.5M). Within this direct 5-issuer industry benchmark cohort, ELTX leads on earnings valuation at N/A trailing P/E, while DWTX leads on capital efficiency and profitability with -32.3% ROIC and — gross margin. ATNM currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with ELTX at 28/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ELTX
ACTIVE
Elicio Therapeutics Inc. | E | 28/100 | — | — | -35.0% | -5.36% | $45.5M | Benchmark Subject |
| MREO Mereo BioPharma Group plc | D- | 37/100 | — | — | -35.0% | +0.17% | $46.2M | /mreo-vs-eltx → |
| BMEA Biomea Fusion Inc. | E | 30/100 | — | — | -35.0% | +3.19% | $46.4M | /bmea-vs-eltx → |
| ATNM Actinium Pharmaceuticals Inc. (Delaware) | D- | 43/100 | — | — | -35.0% | -3.38% | $46.5M | /atnm-vs-eltx → |
| DWTX Dogwood Therapeutics Inc. | D- | 38/100 | — | — | -32.3% | -4.69% | $43.5M | /dwtx-vs-eltx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Elicio Therapeutics Inc. (ELTX) reported GAAP revenue of $105.6M (-16.2% vs. FY2024 revenue of $126.0M , and +5.5% cumulative change since FY2023) , GAAP net income of -$39.6M, operating cash flow of -$37.0M, and free cash flow of -$37.0M (+0.5% YoY). On the balance sheet, ELTX closed FY2025 with $25.9M in total assets against $9.4M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $105.6M | -$39.6M | -$37.0M | -$37.0M | $25.9M | $9.4M |
| FY2024 (FY) | 2024-12-31 | $126.0M | -$51.9M | -$37.1M | -$37.2M | $28.2M | $20.0M |
| FY2023 (FY) | 2023-12-31 | $100.1M | -$35.2M | -$32.7M | -$32.7M | — | — |
As of 2026-11-03, Elicio Therapeutics Inc. (NASDAQ: ELTX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $1.59 (-5.36% 1D, market cap $45.5M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ELTX ranks #866 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ELTX carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, MREO (Mereo BioPharma Group plc) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $46.2M) and BMEA (Biomea Fusion Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $46.4M). Among the 5-stock peer group, ELTX leads on earnings multiple (N/A) while DWTX leads on capital efficiency (-32.3% ROIC).
Per ELTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001601485), Elicio Therapeutics Inc. generated $105.6M in revenue (-16.2% YoY), -$39.6M in net income, and -$37.0M in free cash flow against $25.9M in total assets and $9.4M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
ELTX last traded at $1.59 (-5.36% on volume of 330,717 shares), positioning the stock -20.90% below its 50-day simple moving average ($2.01) and -76.34% below its 200-day simple moving average ($6.72). Across its 52-week range of $1.44 to $16.00, ELTX sits at the 1.0% percentile with a 14-day RSI of 42.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.39 to $1.79).
Elicio Therapeutics Inc. (ELTX) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.59 (-5.36% 1D, market capitalization $45.5M).
Elicio Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Reported revenue for FY 2025 and FY 2024 is — in each period indicating no reported revenue in those years. — for how the company monetizes its activities.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Elicio Therapeutics Inc. (ELTX) reported $105.6M in annual revenue (up from $126.0M in FY2024, -16.2% YoY) and -$39.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($100.1M revenue, -$35.2M net income) through FY2025, ELTX scaled operating cash flow to -$37.0M and free cash flow to -$37.0M, backed by $25.9M in total assets against $9.4M in total debt.
Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ELTX carries a macro regime beta of 1.00 and gross margin of —.
Real-time company headlines, analyst actions, and sector developments for Elicio Therapeutics Inc. (ELTX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo! Finance Canada report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.
marketscreener.com report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.
The Manila Times report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.
https://www.dars.gov.et/ report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Elicio Therapeutics Inc. (ELTX) market action, institutional positioning, and fundamental catalysts.
Elicio Therapeutics, Inc. (Nasdaq: ELTX) ("Elicio" or the "Company"), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that the
Multiple pre-specified subgroup analyses favored camupepimut (ELI-002 7P), including patients with and without detectable baseline ctDNA.Encouraging disease-free survival outcomes were observed in both ctDNA-negative (HR
Phase 2 AMPLIFY-7P results are slated for presentation at ESMO Congress 2026 and SITC 2026 with a simultaneous Nature Medicine publication, offering a potential clinical catalyst.. When you look under the hood at ELTX, Fundamental Cash Engine is 6/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $16.00. My 12M target is $2.03.
@AlphaFlow_Cap Agree on the RQD 28/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.68 and keeping dry powder in case we test $1.56.
Fading this rally in ELTX at $1.68. With FY 2025 FCF of -$37.0M against $18.6M in cash and zero reported revenue, the company's cash engine scores 6/20 in the RQD rating.. With a beta of 1.0 and the stock sitting at $1.68 (52-wk range $1.44–$16.00), the easy multiple expansion is already priced in.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: